Dual antiplatelet therapy with aspirin and the oral P2Y12 inhibitor clopidogrel as the
cornerstone of treatment for patients with an acute coronary syndrome (ACS) undergoing …

Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor inhibitor is the mainstay
of treatment for acute coronary syndrome (ACS) patients, whether they undergo a …

Antiplatelet therapy with P2Y12-receptor inhibitors has become the cornerstone of medical
treatment in patients with acute coronary syndrome treated with percutaneous coronary …

Guidelines recommend that dual antiplatelet therapy using aspirin and clopidogrel should
be administered to the majority of patients with acute coronary syndromes, including those …

Background To compare the prescription rates, safety, and efficacy of contemporary P2Y 12
inhibitors in acute coronary syndrome (ACS) patients following percutaneous coronary …

Dual antiplatelet therapy consisting of clopidogrel in addition to aspirin has previously been
the standard of care for patients with acute coronary syndromes (ACS) but international …

A cornerstone of medical therapy for patients with acute coronary syndrome (ACS) is dual
antiplatelet therapy, which includes aspirin and a P2Y12 inhibitor. Randomized controlled …

Aims Guidelines recommend the use of potent P2Y12 inhibitors over clopidogrel for the
reduction of ischaemic events in patients with acute coronary syndrome (ACS). However …

Antiplatelet therapy with P2Y12 receptor inhibitors has become the cornerstone of medical
treatment in patients with acute coronary syndrome, after percutaneous coronary …

For 20 years, dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and a
platelet P2Y12 receptor inhibitor, has been the gold standard of antithrombotic …